The spread of antimicrobial resistance continues to be a priority health concern worldwide, 27 necessitating exploration of alternative therapies. Cannabis sativa has long been known to contain 28 antibacterial cannabinoids, but their potential to address antibiotic resistance has only been 29 superficially investigated. Here, we show that cannabinoids exhibit antibacterial activity against 30 MRSA, inhibit its ability to form biofilms and eradicate stationary phase cells persistent to antibiotics. 31 We show that the mechanism of action of cannabigerol is through targeting the cytoplasmic membrane 32 of Gram-positive bacteria and demonstrate in vivo efficacy of cannabigerol in a murine systemic 33 infection model caused by MRSA. We also show that cannabinoids are effective against Gram-negative 34 organisms whose outer membrane is permeabilized, where cannabigerol acts on the inner membrane.
culture containing sub-MIC concentrations of CBG and, again, no change in the MIC of CBG was 160 detected (Fig. 2 ). While these experiments were unsuccessful probes of mechanism, they suggested 161 very low rates of resistance for CBG, a highly desirable property for an antibiotic. 162 We turned to chemical genomic analysis to generate hypotheses for the target of CBG. Such 163 studies can reveal patterns of sensitivity among genetic loci that are characteristic of the mechanism of 164 action of an antibacterial compound 21 . We confirmed that the model Gram-positive bacterium B. 165 subtilis was susceptible to CBG (MIC 2 µg/mL), and screened a CRISPR interference knockdown 166 library, of all essential genes in B. subtilis 22 for further sensitization to CBG. In the absence of 167 induction, relying on basal repression (which leads to a ~3-fold repression of the knockdown library 22 ), 168 we were unable to detect any knockdowns sensitized to sub-lethal concentrations of CBG (Fig. 2) . 169 Low-level induction identified some sensitive and some suppressing clones, however follow-on work 170 with the individual knockdowns in liquid culture via full checkerboard analysis (combining xylose, the 171 inducer, with CBG) failed to confirm sensitivity or suppression. In all, we were unable to identify bona 172 fide chemical genetic interactions among essential genes of B. subtilis and CBG. We next aimed to 173 query the non-essential gene subset, this time using the Nebraska Transposon Mutant Library, a 174 sequence-defined transposon mutant library consisting of 1,920 strains, each containing a single 175 mutation within a nonessential gene of CA-MRSA USA300 23 , again looking for genetic enhancers or 176 suppressors to generate target hypotheses ( Fig. 2, Supplementary Fig. 3a ). While we were unable to 177 uncover genetic suppressors at supra-lethal concentrations of CBG, we identified 41 transposons as 178 sensitive across 3 different sub-lethal concentrations of CBG (Supplementary Table 2 ). Analysis of 179 these transposons revealed a significant enrichment for genes encoding proteins that are localized at the 180 cytoplasmic membrane ( Supplementary Fig. 3b ) and enrichment for genes encoding functions in 181 processes that take place at the cytoplasmic membrane, such as cellular respiration and electron 182 transport chain ( Supplementary Fig. 3c ). In all, chemical genomic profiling with CBG generally linked 183 its activity to cytoplasmic membrane function.
184
The lack of clear targets among the essential gene products, the predominance of chemical 185 genetic interactions linked to membrane function, and the difficulty generating resistant mutants, 186 suggested that CBG might act on the cytoplasmic membrane of MRSA. Indeed, the propensity of 187 membrane-active compounds to generate resistance is frequently low 24 . Further, the bacterial 188 membrane is critical for cell function and survival, and is essential irrespective of the metabolic status 189 of the cell, including non-growing and persisting cells 24 . The strong action of CBG on persister cells 190 would be consistent with such a mode of action. Thus, we assessed the ability of CBG to disrupt 191 membrane function using the membrane potential-sensitive probe, 3,3'-dipropylthiadicarbocyanine iodide (DiSC3 (5)). In DiSC3-loaded MRSA cells, CBG caused a dose-dependent increase in 193 fluorescence that occurred at a concentration consistent with the MIC of CBG (Fig. 2) . To probe the 194 possibility that CBG selectively dissipated membrane potential (Δψ) component of proton motive 195 force, we tested for synergy with sodium bicarbonate, a known perturbant of ΔpH, that has been shown 196 to synergize with molecules that reduce Δψ 25 . A lack of synergy between these compounds suggested 197 CBG disrupts the integrity of the cytoplasmic membrane ( Supplementary Fig. 4 ).
198
Having established strong in vitro potency for CBG against MRSA, we next sought to evaluate 199 the in vivo efficacy in a murine systemic infection model of MRSA. The effect of CBG on a systemic 200 infection mediated by the CA-MRSA USA300 strain is shown in Fig. 3 . Given that no signs of acute 201 toxicity were reported in a pharmacokinetic study of 120-mg/kg doses of CBG 26 , we used a dose of 100 202 mg/kg in this study. CBG displayed a significant reduction in bacterial burden in the spleen by a factor 203 of 2.8-log10 in CFU compared to the bacterial titer seen with the vehicle (p < 0.001, Mann-Whitney U-204 test). Overall, CBG displayed promising levels of efficacy in the systemic infection model.
205
To date, antibacterial activity of cannabinoids against Gram-negative organisms has largely 206 been ruled out, since reported MICs values fall in the 100-200 µg/mL range 7-8 . We confirmed this, 207 obtaining MICs >128 µg/mL for all of the tested cannabinoids against the model Gram-negative 208 organism Escherichia coli. Given the observed action of CBG on the cytoplasmic membrane of MRSA, 209 we reasoned that CBG (and other cannabinoids) might be equally effective on the Gram-negative 210 counterpart, the inner membrane. Further, just as many antibacterial compounds fail to work against 211 Gram-negative pathogens due to a permeability barrier 27 , we reasoned that low permeability across the 212 outer membrane (OM) may be the reason for the poor efficacy of cannabinoids. Thus, we investigated 213 the antibacterial profile of the five major cannabinoids against E. coli, where their permeation was 214 facilitated through the OM by means of chemical perturbation. To this end, we set up checkerboard 215 assays to assess the interaction of CBG ( Fig. 4a ) and the four other main cannabinoids (Supplementary Indeed, all interactions were deemed synergistic ( Fig. 4, Supplementary Fig. 5 ). For example, CBG, 219 which was inactive against E. coli (>128 µg/mL), was strongly potentiated when combined with a sub-220 lethal concentration of polymyxin B (1 µg/mL in the presence of 0.062 µg/mL polymyxin B). We 221 further assessed whether OM perturbation by genetic means would lead to similar results by evaluating 222 the activity of CBG against a number of strains where the OM was compromised (Fig. 4b) . In an E. coli 223 ΔbamBΔtolC deletion strain, which renders E. coli hyperpermeable to many small molecules, due to 224 loss of BamB, a component of the β-barrel assembly machinery for OM proteins and TolC, the efflux 225 channel in the outer membrane, CBG had a MIC of 4 µg/mL, on par with its Gram-positive activity.
226
Similarly, in a hyperporinated, 9 strain of E. coli, where a recombinant pore was introduced in the 227 OM and all nine known TolC-dependent transporters deleted 28 , CBG activity became evident with a 228 MIC of 8 µg/mL. Finally, in an Acinetobacter baumannii deficient in lipooligosaccharide (LOS-), 229 which effectively alters the permeability of the OM 29 , CBG activity was enhanced greater than 128-230 fold, resulting in a MIC value of 0.5 µg/mL. Overall, these results suggest that cannabinoids face a 231 permeability barrier in Gram-negative bacteria and further imply that cannabinoids inhibit a bacterial 232 process present in Gram-negative pathogens, and likely common to that in Gram-positive pathogens.
233
To this end, we investigated whether CBG acted on the inner membrane (IM) of E. coli as well 234 as the OM, presumably as a consequence of nonspecific membrane effects, as reported for many 235 membrane-active agents. IM and OM permeability were determined, respectively, from ortho-
236
Nitrophenyl-β-galactoside (ONPG) and nitrocefin hydrolysis in an E. coli strain constitutively 237 expressing a cytoplasmic β-galactosidase and a periplasmic β-lactamase while lacking the lactose 238 permease, as described in the literature 30 . As shown in Fig. 4c , CBG specifically acted on the IM, and 239 only in the presence of polymyxin B at a sub-lethal concentration that had minimal effects on the IM 240 alone. We observed that CBG (+polymyxin B) induced major permeability changes in the inner 241 membrane, indicated by a marked increase in optical density values due to ONPG hydrolysis as a result 242 of unmasking the cytoplasmic β-galactosidase, which can only occur with destabilization of IM, was 243 time dependent ( Fig. 4c ). CBG exhibited no action on the OM ( Supplementary Fig. 6 ). Overall, the 244 mechanism of bacterial killing by CBG in E. coli is likely loss of IM integrity and requires antecedent 245 OM permeabilization.
246
Combination antibiotic therapy is becoming an increasingly attractive approach to combat 247 resistance 31 . So too is the strategy of using an OM perturbing molecule to facilitate the permeation of 248 compounds that are otherwise active only on Gram-positive bacteria 32 . We assessed the therapeutic 249 potential of the adjuvant polymyxin B in combination with CBG to inhibit the growth of priority Gram-250 negative pathogens such as A. baumannii, E. coli, Klebsiella pneumoniae, and Pseudomonas 251 aeruginosa (Fig. 4d ). We employed conventional checkerboard assays to determine the interaction and isolates. In all cases, synergy was evident, suggesting the potential for combination therapy of the 254 cannabinoids with polymyxin B against Gram-negative bacteria. Of note, the activity of CBG does not 255 seem to be affected by antibiotic-resistance mechanisms that are limiting the use of other antibiotics 256 and works effectively regardless of the susceptibility profile of the causative organism.
257
In summary, we have investigated the therapeutic potential of cannabinoids, and specifically 258 CBG, through a comprehensive study of in vitro potency on biofilms and persisters, as well as 259 mechanism of action studies and in vivo efficacy experiments. Most notably, we have uncovered the 260 hidden broad-spectrum antibacterial activity of cannabinoids and demonstrated the potential of CBG 261 against Gram-negative priority pathogens. Taken together, our findings lend credence to the idea that 262 cannabinoids may be produced by Cannabis sativa as a natural defense against plant pathogens. CBG was synthesized using a reported procedure 40 . To a 25 mL round-bottomed flask containing a 345 magnetic stir were added olivetol (108 mg, 0.6 mmol), chloroform (5 mL), geraniol (174 µL, 1.0 346 mmo), p-toluene sulfonic acid monohydrate (19 mg, 0.1 mmol) . The flask was covered with aluminum 347 foil and the reaction was stirred at room temperature in the dark for 12 hours at which point TLC 348 analysis indicated complete consumption of the olivetol substrate. To the reaction was added aqueous 349 saturated NaHCO3 (5 mL). The organic phase was removed and washed with water (5 mL). The 89, 139.13, 132.19, 123.89, 121.84, 110.73, 108.52, 39.83, 35.65, 31.63, 30.93, 26.52, 25.81, 358 22.68, 22.40, 17.83, 16.32, 14.16 . 
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